(LEGN) Legend Biotech Corporation Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LEGN) Legend Biotech Corporation Complete Analysis Pack
Download Your Competitive Advantage
This Legend Biotech Corporation 4P's Marketing Mix Analysis explains the company’s products, pricing, distribution, and promotion in a concise, actionable format and shows how these elements support market positioning and sales. The page includes a real preview/sample of the analysis so you can review style and content; purchase the full version to download the complete ready-to-use report.
Product
CARVYKTI (ciltacabtagene autoleucel)
CARVYKTI (ciltacabtagene autoleucel) is Legend Biotech Corporation's lead BCMA-directed CAR-T for multiple myeloma and its core revenue driver. In 2025, Johnson & Johnson reported CARVYKTI net sales of about $1.0 billion, up sharply from 2024, showing strong demand in relapsed or refractory disease. It is the main commercial product in Legend Biotech's 4P mix and anchors pricing, promotion, and channel strategy.
LCAR-B38M program
LCAR-B38M is the clinical name behind CARVYKTI, and it proved Legend Biotech Corporation could build a CAR-T franchise in revlimid-refractory multiple myeloma. In early studies, it delivered deep responses, including an overall response rate above 90% in heavily pretreated patients. That data built Legend's hematology platform and gave the product real commercial pull.
CD20 CAR-T candidate
Legend Biotech Corporation's CD20 CAR-T candidate targets B-cell malignancies and broadens its cell-therapy pipeline beyond BCMA. The move matters because B-cell cancers remain a large market, while Legend's 2025 base is still anchored by CARVYKTI, which drove $1.1 billion in 2025 net product sales. Any CD20 success could deepen its oncology reach and reduce single-target reliance.
CD22 and CD19 CAR-T candidates
Legend Biotech Corporation's CD22 and CD19 CAR-T candidates extend its reach beyond the lead BCMA franchise into three B-cell cancers: non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia.
That matters because these hematologic cancers still drive large unmet need, and CD19 already anchors approved CAR-T care in the class. The two targets give Legend Biotech Corporation a broader oncology pipeline and more shots at future value.
- Targets: CD22, CD19
- Focus: 3 cancer types
- Effect: broader oncology reach
Solid tumor and infectious disease assets
Legend Biotech Corporation's solid tumor and infectious disease assets are still early preclinical and clinical programs, but they matter because they show the platform is not limited to blood cancers. That wider scope can support long-term pipeline value if one or more programs advance beyond proof-of-concept.
In FY2025, Legend Biotech still depended on hematology-led CAR-T revenue, so these non-blood-cancer assets remain option value rather than near-term sales drivers. The key signal is strategic breadth, not current commercial scale.
- Early-stage assets beyond blood cancers
- Includes solid tumor and infectious disease programs
- Supports a broader platform strategy
CARVYKTI Drives Legend Biotech’s 2025 Growth
Legend Biotech Corporation’s Product mix is led by CARVYKTI, the BCMA CAR-T for relapsed or refractory multiple myeloma. Johnson & Johnson reported about $1.0 billion of CARVYKTI net sales in 2025, up sharply from 2024. That made it the clear core of Legend Biotech Corporation’s product strategy.
| Metric | 2025 |
|---|---|
| CARVYKTI net sales | About $1.0 billion |
| Core product | BCMA CAR-T |
| Pipeline scope | CD20, CD22, CD19 |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Legend Biotech’s product, pricing, placement, and promotion strategies.
Editable Excel File
Turns Legend Biotech’s 4Ps into a quick, easy-to-scan snapshot that reduces analysis overload and speeds decision-making.
Reference Sources
Provides a concise, traceable list of primary industry reports, clinical data, and regulatory sources to speed due diligence and validate Legend Biotech assumptions.
Place
Somerset, New Jersey headquarters
Legend Biotech Corporation’s headquarters in Somerset, New Jersey is its corporate center and the base for U.S. operations. It helps coordinate commercialization, research, and the company’s partnerships, including work tied to CARVYKTI. The New Jersey location also keeps leadership close to major U.S. biotech, regulatory, and investor networks.
United States market
The United States is Legend Biotech Corporation's core commercial market for CARVYKTI, sold through U.S. oncology channels and routed to certified specialty treatment sites. In 2025, this high-touch model fit a therapy used after 1 prior line of treatment and supported access in complex multiple myeloma care. U.S. launch spend stays concentrated on site activation, referral flow, and patient logistics.
China market
Legend Biotech Corporation operates in China through its Nanjing base, where the company supports cell-therapy development, manufacturing, and regional business activity. China remains a key geography because it gives Legend access to a large oncology market and local talent for process and clinical work. The company’s China footprint also helps scale production and support CAR-T execution across Asia.
International markets
Legend Biotech Corporation sells CARVYKTI outside the U.S. and China through Europe and other licensed markets, which widens patient access and lifts commercial reach. In 2024, Johnson & Johnson said CARVYKTI generated $963 million in global net sales, up 91% year over year, and international approvals kept expanding the addressable pool. This global footprint also strengthens Legend Biotech Corporation’s regulatory playbook for new filings and label growth.
- Broader access beyond U.S. and China
- Supports global regulatory expansion
- Boosts commercial scale and reach
Janssen commercialization network
Janssen’s commercialization network widens Legend Biotech Corporation’s reach by plugging ciltacabtagene autoleucel into Johnson & Johnson’s global sales and medical-affairs channels. In 2024, CARVYKTI net sales for Johnson & Johnson hit $963 million, showing the scale of that channel. This joint model shares development and launch work across major markets, so access is faster and broader.
Legend Biotech’s U.S.-China hub powers CARVYKTI access
Legend Biotech Corporation keeps "Place" centered on Somerset, New Jersey and Nanjing, China, while CARVYKTI is delivered through certified U.S. oncology sites and Johnson & Johnson’s global channel. In 2025, this setup kept access tied to specialist treatment centers, which matters for a one-time CAR-T therapy.
| Area | Role |
|---|---|
| Somerset, NJ | U.S. HQ |
| Nanjing, China | R&D and manufacturing |
| U.S. sites | Certified CARVYKTI delivery |
| Global J&J network | Broader market reach |
What You See Is What You Get
Legend Biotech Corporation Reference Sources
The preview shown here is the exact Legend Biotech 4P's Marketing Mix analysis you'll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Janssen partnership visibility
The Janssen alliance is a strong promotional signal for Legend Biotech Corporation because it ties CARVYKTI to Johnson & Johnson’s global oncology brand. In 2024, CARVYKTI posted $963 million in sales, up 92% year over year, which shows the partnership is helping drive reach and trust. That large-pharma backing also lifts recognition with oncologists and payers, which matters for a complex cell therapy.
Clinical trial data
Legend Biotech promotes CARVYKTI with clinical trial data, led by CARTITUDE-4, which showed a 74% lower risk of progression or death versus standard triplet therapies in relapsed or refractory multiple myeloma. Efficacy and safety are the core message, backed by deep, durable responses and manageable toxicity. In the pivotal label data, cytokine release syndrome occurred in 84% of patients and neurotoxicity in 11%.
Medical congress presentations
Legend Biotech Corporation uses oncology congresses like ASCO and ASH to present clinical data directly to hematology and oncology specialists. In 2025, CARVYKTI net trade sales reached $1.9 billion, so these meetings support both data readouts and demand. This channel is high-value because it reaches prescribers who drive treatment adoption.
Regulatory milestone news
Regulatory milestones keep Legend Biotech Corporation in the news, and CARVYKTI’s U.S. label expansion in 2024 widened its reach into earlier-line multiple myeloma. Each approval or label update creates fresh visibility for physicians, investors, and patients, while also reinforcing brand trust. In 2025, the company’s scale stayed tied to this regulatory momentum, with CARVYKTI as its only approved product.
- Label updates drive steady news flow.
- Approvals lift physician and patient awareness.
- Regulatory wins support investor confidence.
HCP education
HCP education is central to Legend Biotech Corporation’s CAR-T promotion because CARVYKTI is delivered only through specialized centers, so physicians need clear guidance on referral, eligibility, and treatment timing. The message must also cover leukapheresis, bridging therapy, and post-infusion monitoring for CRS and neurotoxicity, since these steps drive real-world access and use.
- Teach referral paths early
- Explain eligibility and logistics
- Train on CRS and neurotoxicity
CARVYKTI Promotion Gains Traction as Sales Surge to $1.9B
Promotion for Legend Biotech Corporation centers on CARVYKTI data, and the message is strongest when tied to Janssen’s global reach. In 2025, CARVYKTI net trade sales hit $1.9 billion, showing the promotion-to-demand link is working. Congress talks, label wins, and HCP training keep awareness high in myeloma care.
| Promotion lever | Key data |
|---|---|
| Janssen alliance | Global oncology reach |
| CARVYKTI sales | $1.9 billion in 2025 |
| Clinical proof | 74% lower progression risk |
| Safety message | CRS 84%, neurotoxicity 11% |
Price
CARVYKTI U.S. list price about $465,000
CARVYKTI’s U.S. wholesale acquisition cost is about $465,000 per treatment, putting Legend Biotech Corporation in the premium oncology cell-therapy tier. It is a one-time infusion, so the sticker price is high but not recurring like chronic therapies. That price point supports a high-value positioning in the 4P mix, especially in a market where curative intent can justify six-figure oncology spend.
Single-infusion pricing
CARVYKTI is given as one infusion after manufacturing, so Legend Biotech Corporation books an upfront, not monthly, price. That fits a one-and-done model and avoids chronic dosing revenue. In 2025, this cell therapy still relied on a single treatment event, with no repeat maintenance schedule built into the regimen.
Reimbursement-dependent net price
Legend Biotech Corporation’s realized price for CARVYKTI is reimbursement-dependent, so payer coverage and prior authorization shape the net price more than the sticker price. In 2025, this still runs through specialty hospitals and oncology centers under the medical benefit channel, which is standard for CAR-T therapies. That channel helps control access, site-of-care, and reimbursement timing.
Value-based pricing position
Legend Biotech Corporation’s pricing is value-based: CAR-T manufacturing is complex, and one infusion of CARVYKTI carries a U.S. list price of about $465,000. That premium fits a therapy aimed at durable benefit in relapsed/refractory multiple myeloma, where 2024 CARVYKTI sales reached $963 million.
- High price reflects complex cell therapy
- Priced above standard oncology drugs
- Value tied to durable response potential
Pipeline prices not public
Legend Biotech Corporation’s pipeline has no public launch prices yet, so there is no official list price to cite. Early-stage candidates will be priced only after indication, approval status, and payer access are clear; for now, pricing remains undisclosed.
- No public launch price yet
- Price depends on indication
- Approval status will drive pricing
- Payer access will shape net price
CARVYKTI: A Premium One-Time CAR-T With a ~$465K List Price
CARVYKTI stayed a premium one-time CAR-T product in 2025, with a U.S. wholesale acquisition cost near $465,000 per infusion. Net price still depended on payer coverage and prior authorization, so realized pricing was lower and less visible than the list price.
| Metric | Value |
|---|---|
| U.S. WAC | ~$465,000 |
| 2024 sales | $963 million |
| Dosing | One infusion |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.